Sandbox:iqra: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 39: Line 39:
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive
| colspan="2" |Cirrhosis
! colspan="2" align="center" style="background:#DCDCDC;" |Cirrhosis
|
|
|
|
Line 66: Line 66:
|
|
|-
|-
| colspan="2" |Heart failure
! colspan="2" align="center" style="background:#DCDCDC;" |Heart failure
|
|
|
|
Line 93: Line 93:
|
|
|-
|-
| colspan="2" |Thrombosis of portal, hepatic, or splenic veins
! colspan="2" align="center" style="background:#DCDCDC;" |Thrombosis of portal, hepatic, or splenic veins
|
|
|
|
Line 121: Line 121:
|-
|-
! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
| colspan="2" |Lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" |Lymphoma
|
|
|
|
Line 148: Line 148:
|
|
|-
|-
| colspan="2" |Leukemias
! colspan="2" align="center" style="background:#DCDCDC;" |Leukemias
|
|
|
|
Line 175: Line 175:
|
|
|-
|-
| colspan="2" |Polycythemia Vera
! colspan="2" align="center" style="background:#DCDCDC;" |Polycythemia Vera
|
|
|
|
Line 202: Line 202:
|
|
|-
|-
| colspan="2" |Multiple myeloma
! colspan="2" align="center" style="background:#DCDCDC;" |Multiple myeloma
|
|
|
|
Line 229: Line 229:
|
|
|-
|-
| colspan="2" |Essential thrombocythemia
! colspan="2" align="center" style="background:#DCDCDC;" |Essential thrombocythemia
|
|
|
|
Line 256: Line 256:
|
|
|-
|-
| colspan="2" |Primary myelofibrosis
! colspan="2" align="center" style="background:#DCDCDC;" |Primary myelofibrosis
|
|
|
|
Line 283: Line 283:
|
|
|-
|-
| colspan="2" |Primary splenic tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Primary splenic tumors
|
|
|
|
Line 310: Line 310:
|
|
|-
|-
| colspan="2" |Metastatic solid tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Metastatic solid tumors
|
|
|
|
Line 338: Line 338:
|-
|-
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
|Viral
! align="center" style="background:#DCDCDC;" |Viral
|Hepatitis, infectious mononucleosis, cytomegalovirus
! align="center" style="background:#DCDCDC;" |Hepatitis, infectious mononucleosis, cytomegalovirus
|
|
|
|
Line 366: Line 366:
|
|
|-
|-
|Bacterial
! align="center" style="background:#DCDCDC;" |Bacterial
|Salmonella, Brucella, tuberculosis
! align="center" style="background:#DCDCDC;" |Salmonella, Brucella, tuberculosis
|
|
|
|
Line 394: Line 394:
|
|
|-
|-
| rowspan="2" |Parasitic  
! rowspan="2" align="center" style="background:#DCDCDC;" |Parasitic  
|Malaria, schistosomiasis, toxoplasmosis
! align="center" style="background:#DCDCDC;" |Malaria, schistosomiasis, toxoplasmosis
|
|
|
|
Line 422: Line 422:
|
|
|-
|-
|Kala-azar (visceral leishmaniasis)
! align="center" style="background:#DCDCDC;" |Kala-azar (visceral leishmaniasis)
|
|
|
|
Line 449: Line 449:
|
|
|-
|-
| colspan="2" |Infective endocarditis
! colspan="2" align="center" style="background:#DCDCDC;" |Infective endocarditis
|
|
|
|
Line 476: Line 476:
|
|
|-
|-
| colspan="2" |Fungal
! colspan="2" align="center" style="background:#DCDCDC;" |Fungal
|
|
|
|
Line 504: Line 504:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
| colspan="2" |Sarcoid
! colspan="2" align="center" style="background:#DCDCDC;" |Sarcoid
|
|
|
|
Line 531: Line 531:
|
|
|-
|-
| colspan="2" |Serum sickness
! colspan="2" align="center" style="background:#DCDCDC;" |Serum sickness
|
|
|
|
Line 558: Line 558:
|
|
|-
|-
| colspan="2" |Systemic lupus erythematosus
! colspan="2" align="center" style="background:#DCDCDC;" |Systemic lupus erythematosus
|
|
|
|
Line 585: Line 585:
|
|
|-
|-
| colspan="2" |Felty syndrome
! colspan="2" align="center" style="background:#DCDCDC;" |Felty syndrome
|
|
|
|
Line 613: Line 613:
|-
|-
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infiltrative
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infiltrative
| colspan="2" |Gaucher disease
! colspan="2" align="center" style="background:#DCDCDC;" |Gaucher disease
|
|
|
|
Line 640: Line 640:
|
|
|-
|-
| colspan="2" |Niemann-Pick disease
! colspan="2" align="center" style="background:#DCDCDC;" |Niemann-Pick disease
|
|
|
|
Line 667: Line 667:
|
|
|-
|-
| colspan="2" |Amyloidosis
! colspan="2" align="center" style="background:#DCDCDC;" |Amyloidosis
|
|
|
|
Line 694: Line 694:
|
|
|-
|-
| colspan="2" |Langerhans cell histiocytosis
! colspan="2" align="center" style="background:#DCDCDC;" |Langerhans cell histiocytosis
|
|
|
|
Line 721: Line 721:
|
|
|-
|-
| colspan="2" |Hemophagocytic lymphohistiocytosis
! colspan="2" align="center" style="background:#DCDCDC;" |Hemophagocytic lymphohistiocytosis
|
|
|
|
Line 748: Line 748:
|
|
|-
|-
| colspan="2" |Rosai-Dorfman disease
! colspan="2" align="center" style="background:#DCDCDC;" |Rosai-Dorfman disease
|
|
|
|
Line 776: Line 776:
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic (hypersplenic) states
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic (hypersplenic) states
| colspan="2" |Hemolytic anemia
! colspan="2" align="center" style="background:#DCDCDC;" |Hemolytic anemia
|
|
|
|
Line 803: Line 803:
|
|
|-
|-
| colspan="2" |Sickle cell disease
! colspan="2" align="center" style="background:#DCDCDC;" |Sickle cell disease
|
|
|
|
Line 830: Line 830:
|
|
|-
|-
| colspan="2" |Granulocyte colony-stimulating factor
! colspan="2" align="center" style="background:#DCDCDC;" |Granulocyte colony-stimulating factor
|
|
|
|

Revision as of 21:58, 25 September 2018

Splenomegaly differential:

Category Disease Etiology Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs Lab Findings Imaging
Fever Fatigue Weight loss SOB Bleeding BP JVP Jaundice Ascites Other CBC PS Iron LFT PT/PTT BUN/Cr UA
WBC Hb Plt
Congestive Cirrhosis
Heart failure
Thrombosis of portal, hepatic, or splenic veins
Malignancy Lymphoma
Leukemias
Polycythemia Vera
Multiple myeloma
Essential thrombocythemia
Primary myelofibrosis
Primary splenic tumors
Metastatic solid tumors
Infection Viral Hepatitis, infectious mononucleosis, cytomegalovirus
Bacterial Salmonella, Brucella, tuberculosis
Parasitic Malaria, schistosomiasis, toxoplasmosis
Kala-azar (visceral leishmaniasis)
Infective endocarditis
Fungal
Inflammation Sarcoid
Serum sickness
Systemic lupus erythematosus
Felty syndrome
Infiltrative Gaucher disease
Niemann-Pick disease
Amyloidosis
Langerhans cell histiocytosis
Hemophagocytic lymphohistiocytosis
Rosai-Dorfman disease
Hematologic (hypersplenic) states Hemolytic anemia
Sickle cell disease
Granulocyte colony-stimulating factor
Category Disease Etiology Demography History Fever Fatigue Weight loss SOB Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt PS Iron LFT PT/PTT BUN/Cr UA Imaging Gold standard Associated findings
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:iqra&oldid=1495402"